FlexPro® can be used with Novo Nordisk ultra-thin, ultra-short needles – including NovoTwist®, NovoFine®, and NovoFine® Autocover® – designed for ease of use and less pain and anxiety during injection. Please ask your doctor for more information.
FlexPro® is a registered trademark of Novo Nordisk Health Care
AG.
FlexPro® PenMate® is a registered trademark of Novo
Nordisk A/S.
NovoTwist®, NovoFine®, and
NovoFine® Autocover® are registered trademarks of Novo Nordisk A/S.
Availability of Novo Nordisk growth hormone devices and strengths varies by country.
Important Note: The content of this website is not intended to be a substitute for professional medical advice, diagnosis or treatment. Do not disregard your doctor's advice or delay in seeking it because of something you have read in this website.
1. Rohrer TR, Horikawa R, Kappelgaard AM. Growth hormone delivery devices: current features and potential for enhanced treatment adherence [published correction appears in Expert Opin Drug Deliv. 2017;14(8):1025. doi:10.1080/17425247.2017.1263424]. Expert Opin Drug Deliv. 2017;14(11):1253-1264.
2. Miller BS, Blair JC, Rasmussen MH, et al. Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107(12):3378-3388
3. Norditropin FlexPro Summary of Product Characteristics. November 2022